Based on these findings, HDAC6 inhibition represents a new and promising avenue to treat PAH, avoiding the unforeseeable undesirable side effects caused by non-specific nuclear HDAC inhibitors. Here, HDAC9 is linked to pulmonary arterial hypertension.